Highlights
- CSL (ASX:CSL) appointed Deborah Waterhouse as chief executive from 1 February 2027.
- Gordon Naylor is due to succeed Brian McNamee as chair on 31 March 2027.
- October's AGM reaffirmed FY27 group Revenue and Underlying Profit guidance.
- A 20 November buy-back filing reported 82,396 shares repurchased on the preceding day.
CSL Limited (ASX:CSL) develops and supplies plasma-derived medicines, influenza vaccines and therapies for rare diseases through its international biotechnology businesses. Its shares traded at AUD 196.39 on 20 November 2026, down 1.73% during the session. The company's recent Leadership appointments and October Annual General Meeting have placed executive succession and operational changes in focus.
October disclosures set out who will oversee the next phase, while November buy-back notices provide continuing updates on Capital management.
Chief Executive and Board Succession
In October, the board announced that Deborah Waterhouse would become chief executive officer and managing director on 1 February 2027. She was then chief executive of ViiV Healthcare and had previously managed pharmaceutical and Vaccine businesses in several markets.
Gordon Naylor, interim chief executive since February 2026, will continue until the appointment takes effect. The separate board announcement confirmed that Brian McNamee would retire as chair and director on 31 March 2027, with Naylor to assume the chairmanship on that date. Carolyn Hewson will become senior independent director.
October AGM Sets Operational Priorities
At the 27 October annual general meeting, management described changes to decision-making, commercial operations and research investment. Measures included ending non-core initiatives, reviewing asset carrying values, strengthening commercial capabilities and accelerating the operational separation of Seqirus.
Management reported US$176 million of pretax savings from its transformation programme in FY26. It outlined expectations of approximately US$400 million in FY27 and up to US$550 million in FY28. These future amounts are targets rather than completed savings.
FY26 Results and FY27 Guidance
At the AGM, CSL reported FY26 group revenue of US$15.8 billion, a 1% decline, and underlying net profit after tax of US$2.8 billion, down 3%. The statutory result was a US$2.6 billion net loss following restructuring and impairment-related charges. Operating Cash Flow was approximately US$3.5 billion, while net Debt to EBITDA stood at 1.8 times.
Management reaffirmed guidance for FY27 revenue to be broadly in line with FY26 and underlying net profit after tax to rise approximately 5% on a constant-currency basis. The company expected Behring and Seqirus to contribute, while Vifor faced generic competition in iron products.
Capital Management and Risk Considerations
CSL began a further AUD 1.1 billion on-market buy-back programme in FY27. Its 20 November regulatory update recorded 82,396 securities repurchased on the previous day, alongside 968,018 bought back before that day.
Execution risks include disruption during leadership changes, timing of Manufacturing improvements, plasma collection costs, product competition and regulatory decisions. The published financial results distinguish underlying profit measures from the statutory loss, an important difference when assessing progress.
What to Watch Next
The first executive milestone is Waterhouse's scheduled February 2027 appointment, followed by the March board-chair transition. Operational reporting can show whether plasma efficiency initiatives and commercial changes are delivering measurable results. Further disclosures may also clarify Seqirus separation progress, Vifor trading conditions and the pace of transformation savings.
The next half-year reporting period ends in December 2026.
Key Insights
Leadership succession and execution of the transformation programme are the central developments for CSL. The FY26 statutory loss contrasts with positive operating cash flow and underlying earnings, while FY27 guidance assumes operational delivery. Subsequent results, changes in management responsibilities and buy-back disclosures are identifiable monitoring points.





_11_20_2026_10_15_01_176408.jpg)
Please wait processing your request...